DK3506935T3 - Neisseria meningitidis-vaccine - Google Patents

Neisseria meningitidis-vaccine Download PDF

Info

Publication number
DK3506935T3
DK3506935T3 DK17765045.4T DK17765045T DK3506935T3 DK 3506935 T3 DK3506935 T3 DK 3506935T3 DK 17765045 T DK17765045 T DK 17765045T DK 3506935 T3 DK3506935 T3 DK 3506935T3
Authority
DK
Denmark
Prior art keywords
vaccine
neisseria meningitidis
meningitidis
neisseria
Prior art date
Application number
DK17765045.4T
Other languages
Danish (da)
English (en)
Inventor
Richard David Kensinger
Steven L Hauser
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of DK3506935T3 publication Critical patent/DK3506935T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK17765045.4T 2016-09-02 2017-09-01 Neisseria meningitidis-vaccine DK3506935T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662383279P 2016-09-02 2016-09-02
US201762468695P 2017-03-08 2017-03-08
US201762505525P 2017-05-12 2017-05-12
PCT/US2017/049856 WO2018045286A1 (en) 2016-09-02 2017-09-01 Neisseria meningitidis vaccine

Publications (1)

Publication Number Publication Date
DK3506935T3 true DK3506935T3 (en) 2024-04-02

Family

ID=59846741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17765045.4T DK3506935T3 (en) 2016-09-02 2017-09-01 Neisseria meningitidis-vaccine

Country Status (24)

Country Link
US (4) US11147866B2 (enExample)
EP (2) EP4309670A3 (enExample)
JP (3) JP6764021B2 (enExample)
KR (2) KR102692762B1 (enExample)
CN (2) CN118236477B (enExample)
AU (2) AU2017321863B2 (enExample)
BR (1) BR112019003992A2 (enExample)
CA (1) CA3033364A1 (enExample)
DK (1) DK3506935T3 (enExample)
ES (1) ES2974992T3 (enExample)
FI (1) FI3506935T3 (enExample)
HR (1) HRP20240433T1 (enExample)
HU (1) HUE066007T2 (enExample)
LT (1) LT3506935T (enExample)
MX (1) MX2019002489A (enExample)
PH (1) PH12019500399B1 (enExample)
PL (1) PL3506935T3 (enExample)
PT (1) PT3506935T (enExample)
RS (1) RS65362B1 (enExample)
SA (1) SA519401227B1 (enExample)
SG (1) SG11201901394XA (enExample)
SI (1) SI3506935T1 (enExample)
WO (1) WO2018045286A1 (enExample)
ZA (1) ZA201901402B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
AU2023254751A1 (en) 2022-04-11 2024-11-21 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
JP7804631B2 (ja) * 2022-11-22 2026-01-22 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
PL175595B1 (pl) * 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DE10012370A1 (de) 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
US6673905B2 (en) 2000-08-09 2004-01-06 The United States Of America As Represented By The Department Of Health And Human Services Conjugation of biomolecules using Diels-Alder cycloaddition
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
WO2003094961A1 (en) 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
AU2003299501A1 (en) 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CN1852733A (zh) 2003-05-07 2006-10-25 安万特巴斯德公司 多价脑膜炎球菌衍生的多糖-蛋白质缀合物及疫苗
US6933137B2 (en) 2003-05-16 2005-08-23 Aventis Pasteur Animal component free meningococcal polysaccharide fermentation and seedbank development
CA2530364C (en) 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
EP1638601B1 (en) 2003-06-23 2008-11-19 Baxter International Inc. Carrier proteins for vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1651262A2 (en) 2003-08-06 2006-05-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Process for preparing polysaccharide-protein conjugate vaccines
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
CU23236A1 (es) 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
KR20070101207A (ko) 2004-08-30 2007-10-16 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
MX2007003292A (es) 2004-09-21 2007-09-07 Sanofi Pasteur Inc Conjugados y vacuna con proteinas de polisacarido derivadas meningococales multivalentes.
WO2006042542A2 (en) 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
MX2007013881A (es) 2005-05-06 2008-10-22 Novartis Vaccines & Diagnostic Inmunogenos para vacunas de meningitides-a.
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0513071D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群c髄膜炎菌を含む複数ワクチン接種
WO2007028408A1 (en) 2005-09-05 2007-03-15 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
BRPI0516372A (pt) 2005-12-22 2008-09-02 Sanofi Pasteur Inc conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1976857A4 (en) 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES
KR101711903B1 (ko) 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
CU23575A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es) 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2654706A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
US7491517B2 (en) 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
BRPI0715396B8 (pt) 2006-08-07 2021-05-25 Harvard College método de produção de uma composição para vacina
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
CA2692069C (en) 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
WO2009006620A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
GB0810894D0 (en) 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP5841044B2 (ja) 2009-03-23 2016-01-06 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 複合糖質ワクチン
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011268507B2 (en) * 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
US9120848B2 (en) 2010-09-23 2015-09-01 Harvey Kaplan Non-aqueous synthesis of polysaccharide-protein conjugates for vaccines
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CN103747798B (zh) 2011-05-18 2018-10-26 马特里瓦克斯公司 包含聚阳离子的蛋白质基质疫苗组合物
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
IN2012MU00206A (enExample) * 2012-01-20 2013-08-09
MX354103B (es) * 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
CN104428008B (zh) 2012-05-24 2020-10-09 美国政府(由卫生和人类服务部的部长所代表) 多价脑膜炎球菌缀合物及制备缀合物的方法
RU2019101166A (ru) 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
CN104487086B (zh) 2012-07-07 2019-08-30 巴拉特生物技术国际有限公司 无动物源的不含酒精的疫苗组合物及其制备方法
DK2885007T3 (en) 2012-08-16 2018-12-03 Pfizer Methods for glycoconjugation and compositions
CN102809656B (zh) 2012-08-26 2014-09-03 云南沃森生物技术股份有限公司 一种脑膜炎球菌多糖结合疫苗成品各群游离多糖含量的测定方法
JP6324961B2 (ja) * 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
WO2014080423A2 (en) 2012-11-21 2014-05-30 Serum Institute Of India Ltd. Production of high yields of bacterial polysaccharides
JP6502262B2 (ja) 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
DK2976101T3 (da) * 2013-03-18 2020-11-23 Glaxosmithkline Biologicals Sa Behandlingsfremgangsmåde
US9782468B2 (en) 2013-05-20 2017-10-10 Shantha Biotechnics Private Limited Purification of polysaccharide protein conjugates
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
MY194920A (en) 2013-10-11 2022-12-23 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
US10378017B2 (en) 2013-12-02 2019-08-13 Brandeis University High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
CN106061986B (zh) 2014-02-25 2020-07-07 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 脑膜炎奈瑟菌血清组x的新的合成寡聚体及其制备方法
MY186874A (en) 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
US10407703B2 (en) 2014-04-17 2019-09-10 Medizinische Hochschule Hannover Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
WO2015181834A2 (en) 2014-05-24 2015-12-03 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
EA201700177A1 (ru) * 2014-10-09 2017-07-31 Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016174683A1 (en) 2015-04-28 2016-11-03 Biological E Limited Method for separation of protein and other impurities from microbial capsular polysaccharides
CN104998255B (zh) 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 新型acyw135群脑膜炎球菌结合疫苗及其制备方法
WO2017006349A1 (en) 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
CN105061629A (zh) 2015-08-31 2015-11-18 成都欧林生物科技股份有限公司 A群脑膜炎球菌荚膜粗多糖纯化工艺
EP3377613A1 (en) 2015-11-17 2018-09-26 Pfizer Inc Media and fermentation methods for producing polysaccharides in bacterial cell culture
JP2019508468A (ja) 2016-03-15 2019-03-28 エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
EP3585427A4 (en) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS

Also Published As

Publication number Publication date
CN118236477A (zh) 2024-06-25
MX2019002489A (es) 2019-10-21
SA519401227B1 (ar) 2022-02-28
JP2019526573A (ja) 2019-09-19
CN109890413B (zh) 2024-04-16
US12611451B2 (en) 2026-04-28
SG11201901394XA (en) 2019-03-28
FI3506935T3 (fi) 2024-04-17
EP3506935A1 (en) 2019-07-10
ES2974992T3 (es) 2024-07-02
RS65362B1 (sr) 2024-04-30
HRP20240433T1 (hr) 2024-07-05
KR20190044663A (ko) 2019-04-30
PT3506935T (pt) 2024-04-01
US11707514B2 (en) 2023-07-25
PH12019500399B1 (en) 2024-05-15
AU2024223993A1 (en) 2024-10-24
US20250152693A1 (en) 2025-05-15
PL3506935T3 (pl) 2024-06-10
EP3506935B1 (en) 2024-01-10
WO2018045286A1 (en) 2018-03-08
JP7028932B2 (ja) 2022-03-02
JP7329087B2 (ja) 2023-08-17
KR102692762B1 (ko) 2024-08-08
KR102906912B1 (ko) 2026-01-05
US20190175718A1 (en) 2019-06-13
BR112019003992A2 (pt) 2019-05-28
US11147866B2 (en) 2021-10-19
CN109890413A (zh) 2019-06-14
US20210401964A1 (en) 2021-12-30
KR20230135178A (ko) 2023-09-22
ZA201901402B (en) 2024-06-26
JP2021001182A (ja) 2021-01-07
US20230310567A1 (en) 2023-10-05
SI3506935T1 (sl) 2024-06-28
HUE066007T2 (hu) 2024-07-28
JP6764021B2 (ja) 2020-09-30
PH12019500399A1 (en) 2019-05-20
CN118236477B (zh) 2025-04-25
AU2017321863B2 (en) 2024-07-11
LT3506935T (lt) 2024-04-25
JP2022065099A (ja) 2022-04-26
AU2017321863A1 (en) 2019-04-11
EP4309670A2 (en) 2024-01-24
CA3033364A1 (en) 2018-03-08
EP4309670A3 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
GB201721459D0 (en) No details
GB201808471D0 (en) No details
GB201805152D0 (en) No details
GB201805549D0 (en) No details
AU201616678S (en) Cylindres
GB201715843D0 (en) No details
GB201715887D0 (en) No details
GB201803296D0 (en) No details
GB201714253D0 (en) No details
GB201622033D0 (en) No details
GB201717272D0 (en) No details
GB201803881D0 (en) No details
GB201717622D0 (en) No details
GB201802686D0 (en) No Details
GB201802295D0 (en) No Details
GB201802603D0 (en) No details
GB201702043D0 (en) No details
GB201709809D0 (en) No details
DK3506935T3 (en) Neisseria meningitidis-vaccine
GB201800519D0 (en) No details
GB201805149D0 (en) No details
GB201801948D0 (en) No details
GB201802121D0 (en) No details
GB201801950D0 (en) No details
GB201703185D0 (en) No details